Richard Douglas has bought stock on 9 days since Sep 2016

Richard H. Douglas, Ph.D., is a biopharmaceutical executive and corporate director who serves as Chair of the Board of Directors of Aldeyra Therapeutics, Inc. and a member of its Nominating and Governance Committee.( He has recently been active as a corporate insider at Aldeyra, including receiving equity-based option grants tied to his service as a director, chairperson of the board, and member of the nominating/governance committee, and purchasing additional Aldeyra common stock in open-market transactions.( Dr. Douglas joined the Aldeyra board in 2016.(

Dr. Douglas is the former Senior Vice President, Corporate Development at Genzyme Corporation, where from 1989 to 2011 he led the corporate development team and was involved in numerous acquisitions, licenses, financings, joint ventures, and strategic alliances.( Before Genzyme’s 1989 merger with Integrated Genetics, he held science and corporate development roles at Integrated Genetics from 1982.( Since 2011, he has worked as an independent consultant and advisor with Red Sky Partners LLC and serves on the boards of Novavax, Inc. and MaxCyte, Inc., both publicly traded clinical-stage biopharmaceutical companies.( He also serves on the University of Michigan Technology Transfer National Advisory Board.( Dr. Douglas holds a B.S. in chemistry from the University of Michigan and a Ph.D. in biochemistry from the University of California, Berkeley, and completed postdoctoral research in Leroy Hood’s laboratory at the California Institute of Technology.(

Written by Perplexity from public sources.